17.1 A RANDOMIZED CONTROLLED TRIAL OF CANNABIDIOL IN SCHIZOPHRENIA

BACKGROUND: Both preclinical and human research suggest that cannabidiol (CBD) has antipsychotic properties. This study assessed the safety and effectiveness of CBD in patients with schizophrenia. METHODS: Patients with schizophrenia (n=88) were randomized to receive CBD (1000 mg/day) or placebo alo...

Descripción completa

Detalles Bibliográficos
Autores principales: McGuire, Philip, Robson, Philip, Cubała, Wiesław, Vasile, Daniel, Morrison, Paul, Barron, Rachel, Taylor, Adam, Wright, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887970/
http://dx.doi.org/10.1093/schbul/sby014.065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887970/
http://dx.doi.org/10.1093/schbul/sby014.065

Ejemplares similares